EmailHospital Circular 13/2007
Date Issued: 29 June 2007
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 July 2007.
We have had recent advice from the Commonwealth Government of a change to the Highly Specialised Drugs Program, effective 1 July 2007.
Amended Restrictions
Lanreotide acetate |
||||
| 6332G | Powder for suspension for injection 30mg (base) with diluent ampoule | 1 | Somatuline LA | IS |
| 6423C | Injection 60mg (base) single dose pre-filled syringe | 1 | Somatuline Autogel | IS |
| 6424D | Injection 90mg (base) single dose pre-filled syringe | 1 | Somatuline Autogel | IS |
| 6425E | Injection 120mg (base) single dose pre-filled syringe | 1 | Somatuline Autogel | IS |
| Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | ||||
Octreotide acetate |
||||
| 6227R | Injection 50mcg (base) in 1ml | 5 | Sandostatin 0.05 | NV |
| 6228T | Injection 100mcg (base) in 1ml | 5 | Sandostatin 0.1 | NV |
| 6229W | Injection 500mcg (base) in 1ml | 5 | Sandostatin 0.5 | NV |
| 6426F | Injection (modified release) 10mg (base) vial and diluent syringe | 1 | Sandostatin LAR | NV |
| 6427G | Injection (modified release) 20mg (base) vial and diluent syringe | 1 | Sandostatin LAR | NV |
| 6428H | Injection (modified release) 30mg (base) vial and diluent syringe | 1 | Sandostatin LAR | NV |
| Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | ||||
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Dr Jennifer King
Director, Programs
Metropolitan Health & Aged Care Services
